EWTX vs. GPCR, KURA, SUPN, TARO, SYRE, SDGR, RCUS, HRMY, LGND, and PTGX
Should you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Structure Therapeutics (GPCR), Kura Oncology (KURA), Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Spyre Therapeutics (SYRE), Schrödinger (SDGR), Arcus Biosciences (RCUS), Harmony Biosciences (HRMY), Ligand Pharmaceuticals (LGND), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical preparations" industry.
Structure Therapeutics (NASDAQ:GPCR) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Structure Therapeutics currently has a consensus price target of $85.71, suggesting a potential upside of 137.63%. Edgewise Therapeutics has a consensus price target of $31.20, suggesting a potential upside of 76.47%. Given Edgewise Therapeutics' higher probable upside, equities analysts plainly believe Structure Therapeutics is more favorable than Edgewise Therapeutics.
In the previous week, Structure Therapeutics and Structure Therapeutics both had 11 articles in the media. Edgewise Therapeutics' average media sentiment score of 1.07 beat Structure Therapeutics' score of 0.59 indicating that Structure Therapeutics is being referred to more favorably in the media.
Structure Therapeutics' return on equity of -29.09% beat Edgewise Therapeutics' return on equity.
Edgewise Therapeutics received 5 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Structure Therapeutics an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.
Structure Therapeutics is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.
91.8% of Structure Therapeutics shares are owned by institutional investors. 32.0% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Structure Therapeutics beats Edgewise Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Edgewise Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edgewise Therapeutics Competitors List
Related Companies and Tools
